Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in Oklahoma: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 126 | 24% |
| 2020 | 3 | 210 | 28% |
| 2021 | 3 | 234 | 34% |
| 2022 | 5 | 217 | 38% |
| 2023 | 7 | 234 | 42% |
| 2024 | 9 | 370 | 44% |
| 2025 from claims | – | 403 326–473 | 46% |
| 2026 forecast | – | 437 343–549 | 46% |
| 2027 forecast | – | 476 353–629 | 47% |
| 2028 forecast | – | 517 366–714 | 48% |
| 2029 forecast | – | 562 382–806 | 49% |
| 2030 forecast | – | 611 400–906 | 49% |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Oklahoma; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 19% inpatient hospital, 27% hospital outpatient, 54% office. The share outside the hospital has moved +36 pts since 2020, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 20 | 1,201+17%/yr | +17%/yr | 0.5 | 59% | 2,330 in 2030+12%/yr |
| Florida | 18 | 1,158+12%/yr | +12%/yr | 0.5 | 66% | 2,840 in 2030+16%/yr |
| Georgia | 7 | 300+10%/yr | +10%/yr | 0.3 | 67% | 370 in 2030+3.5%/yr |
| South Carolina | 3 | 206+39%/yr | +39%/yr | 0.3 | 14% | 340 in 2030+8.7%/yr |
| Tennessee | 3 | 175+24%/yr | +24%/yr | 0.2 | 16% | 320 in 2030+11%/yr |
| Virginia | 3 | 167+8.3%/yr | +8.3%/yr | 0.1 | 0% | 390 in 2030+15%/yr |
| North Carolina | 3 | 167+8.3%/yr | +8.3%/yr | 0.1 | 13% | 340 in 2030+13%/yr |
| Maryland | 2 | 164+22%/yr | +22%/yr | 0.2 | 0% | 290 in 2030+10%/yr |
| Louisiana | 1 | 124+13%/yr | +13%/yr | 0.3 | 0% | 350 in 2030+19%/yr |
| Alabama | 1 | 100+11%/yr | +11%/yr | 0.2 | 0% | 60 in 2030−8.8%/yr |
| Kentucky | 2 | 100−6.4%/yr | −6.4%/yr | 0.2 | 0% | 170 in 2030+8.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Lumbar fusion | 45 | 1,762−4.7%/yr | −4.7%/yr | 3.51.1× | 1% | 1,970 in 2030+1.9%/yr |
| Decompression & minimally invasive spine | 44 | 1,608−8.9%/yr | −8.9%/yr | 3.21.0× | 1% | 1,650 in 2030+0.4%/yr |
| Kyphoplasty & vertebroplasty | 16 | 1,356−6.7%/yr | −6.7%/yr | 2.81.6× | 48% | 1,260 in 2030−1.2%/yr |
| Cervical fusion & disc arthroplasty | 28 | 913−6.1%/yr | −6.1%/yr | 1.81.1× | 0% | 980 in 2030+1.2%/yr |
SI joint fusion in every state, and its device makers · Every procedure market in Oklahoma · Every state · Compare with Texas
Genesys Orthopedics Systems leads with 85% of company spending on these surgeons in 2025, +28 pts on 2024.
In 2025, 6 companies reported engagement with Oklahoma’s surgeons worth $75K in consulting, speaking, meals and travel tied to these products, about $8,307 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.